Apobec-1 Complementation Factor (A1CF) Inhibits Epithelial-Mesenchymal Transition and Migration of Normal Rat Kidney Proximal Tubular Epithelial Cells

Liyuan Huang, Honglian Wang, Yuru Zhou, Dongsheng Ni, Yanxia Hu, Yaoshui Long, Jianing Liu, Rui Peng, Li Zhou, Zhicheng Liu, Zhong‐Shi Lyu, Zhaomin Mao, Jin Hao, Yiman Li, Qin ZhouInternational Journal of Molecular Sciences 2016 · DOI

TL;DR

This study investigates the role of Apobec-1 Complementation Factor (A1CF) in kidney tubular epithelial cells, revealing its potential as a protective factor against kidney fibrosis. The research demonstrates that A1CF inhibits epithelial-mesenchymal transition (EMT), a key process in kidney fibrosis, by upregulating epithelial markers and downregulating mesenchymal markers.

What Problem Does This Paper Address?

Chronic kidney disease (CKD) is a growing global health concern, and kidney fibrosis is a common, detrimental outcome in progressive CKD. A critical cellular process contributing to kidney fibrosis is epithelial-mesenchymal transition (EMT), where kidney tubular epithelial cells transform into myofibroblasts, leading to excessive extracellular matrix deposition. While EMT is well-established as a driver of fibrosis, the specific molecular mechanisms that regulate this transition in the kidney remain an active area of research. A1CF, a protein known for its role in RNA editing in the intestine, is also expressed in the kidneys, but its function in this organ, particularly in relation to kidney disease, was largely unknown. This paper aims to elucidate the role of A1CF in kidney tubular epithelial cells and its potential involvement in the EMT process.

Methods

The researchers employed a multi-pronged approach to investigate A1CF's function:

  • In Situ Hybridization: This technique was used to examine the expression pattern and localization of A1CF mRNA in developing and adult mouse kidneys.
  • Cell Culture: Immortalized rat kidney proximal tubular epithelial cells (NRK52e) were used as a model system.
  • Transfection: Overexpression of A1CF (including two variants, A1CF and A1CF (-8AA)) was achieved by transfecting NRK52e cells with plasmids encoding these proteins.
  • RNA Interference (RNAi): Knockdown of endogenous A1CF was performed using specific siRNAs to assess the consequences of reduced A1CF levels.
  • Western Blotting: This method was used to quantify the protein levels of key epithelial (E-cadherin) and mesenchymal (vimentin, α-SMA) markers in response to A1CF manipulation.
  • Immunofluorescence Staining: This technique allowed for the visualization of the cellular localization and expression levels of E-cadherin, vimentin, and α-SMA, providing spatial insights into EMT.
  • Scratch Wound Healing Assay: This assay was employed to assess the migratory capacity of NRK52e cells, as increased migration is a hallmark of EMT.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • A1CF is a conserved protein with a specific kidney expression pattern: The study highlights that A1CF is highly conserved across species, suggesting a fundamental biological role. Crucially, its expression in the kidney is developmentally regulated, appearing later in embryonic development and becoming prominent in adult kidney tubules, particularly in the inner cortex. This specific localization hints at a role in mature kidney function.
  • A1CF acts as a brake on EMT: The most significant finding is that A1CF actively inhibits EMT. Overexpressing A1CF in kidney tubular cells promotes epithelial characteristics (upregulating E-cadherin) and suppresses mesenchymal traits (downregulating vimentin and α-SMA). Conversely, reducing A1CF levels exacerbates EMT.
  • A1CF variants show similar, but nuanced, effects: The study examined two variants of A1CF (full-length and a variant lacking an eight-amino-acid motif). Both variants inhibited EMT, but the variant lacking the motif showed a stronger inhibitory effect, suggesting this specific motif might play a role in modulating A1CF's function.
  • Inhibition of EMT translates to reduced cell migration: The observed inhibition of EMT by A1CF was further supported by findings that A1CF overexpression reduced the migratory ability of kidney tubular cells, a key characteristic of mesenchymal cells.

Key Results

  • A1CF expression in mouse kidneys begins weakly at embryonic day 15.5 and is strongly expressed in adult kidneys, primarily in the tubules of the inner cortex.
  • Overexpression of A1CF in NRK52e cells led to a significant increase in the epithelial marker E-cadherin and a significant decrease in mesenchymal markers vimentin and α-SMA.
  • Knockdown of A1CF in NRK52e cells resulted in a decrease in E-cadherin and an increase in vimentin and α-SMA, indicating an enhancement of EMT.
  • Both A1CF variants tested inhibited NRK52e cell migration, while A1CF knockdown significantly increased migration.

Limitations and Future Work

The authors acknowledge that while both A1CF variants showed similar trends in inhibiting EMT, the variant lacking the EIYMNVPV motif had a stronger effect. The precise role of this motif and the potential differences in subcellular localization between the variants remain unclear and warrant further investigation. Additionally, the precise molecular mechanisms by which A1CF exerts its anti-EMT effects and its specific role in various kidney disease contexts (e.g., cancer metastasis, kidney injury healing) require further exploration. The study suggests A1CF as a potential therapeutic target for inhibiting kidney fibrosis, but this requires validation in preclinical and clinical settings.

Summary updated

Abstract

Apobec-1 complementation factor (A1CF) is a member of the heterogeneous nuclear ribonucleoproteins (hnRNP) family, which participates in site-specific posttranscriptional RNA editing of apolipoprotein B (apoB) transcript. The posttranscriptional editing of apoB mRNA by A1CF in the small intestine is required for lipid absorption. Apart from the intestine, A1CF mRNA is also reported to be highly expressed in the kidneys. However, it is remained unknown about the functions of A1CF in the kidneys. The aim of this paper is to explore the potential functions of A1CF in the kidneys. Our results demonstrated that in C57BL/6 mice A1CF was weakly expressed in embryonic kidneys from E15.5dpc while strongly expressed in mature kidneys after birth, and it mainly existed in the tubules of inner cortex. More importantly, we identified A1CF negatively regulated the process of epithelial-mesenchymal transition (EMT) in kidney tubular epithelial cells. Our results found ectopic expression of A1CF up-regulated the epithelial markers E-cadherin, and down-regulated the mesenchymal markers vimentin and α-smooth muscle actin (α-SMA) in NRK52e cells. In addition, knockdown of A1CF enhanced EMT contrary to the overexpression effect. Notably, the two A1CF variants led to the similar trend in the EMT process. Taken together, these data suggest that A1CF may be an antagonistic factor to the EMT process of kidney tubular epithelial cells.
BibTeX
@article{huang2016apobec,
  author = {Liyuan Huang and Honglian Wang and Yuru Zhou and Dongsheng Ni and Yanxia Hu and Yaoshui Long and Jianing Liu and Rui Peng and Li Zhou and Zhicheng Liu and Zhong‐Shi Lyu and Zhaomin Mao and Jin Hao and Yiman Li and Qin Zhou},
  title = {{Apobec-1 Complementation Factor (A1CF) Inhibits Epithelial-Mesenchymal Transition and Migration of Normal Rat Kidney Proximal Tubular Epithelial Cells}},
  journal = {International Journal of Molecular Sciences},
  year = {2016},
  doi = {10.3390/ijms17020197},
}
Figure